COVID-19 |  New Chinese vaccine is 79% effective against Delta variant

The Chinese pharmaceutical company Clover Biopharmaceuticals announced that it has developed a vaccine whose trials show an efficacy of 79% in protecting the patient from complications of any severity caused by the Delta variant of SARS-CoV-2, local media reported.

SIGHT: Sinopharm will be accepted to travel to the US: reasons to trust the Chinese vaccine

Likewise, the pharmaceutical company -which plans to supply 414 million doses to the COVAX program- assured that the vaccine, called SCB-19 and protein-based, is 92% and 59% effective against the Gamma and Mu variants, respectively.

The overall efficacy against complications of any severity caused by the coronavirus in any of the three variants analyzed was 67%.

SIGHT: COVID-19 May Look Like a Cold in the Future, According to AstraZeneca Developer

According to Clover, it is the first vaccine to show general efficacy against these three variants.

When it comes to preventing hospitalization for serious complications derived from SARS-CoV-2 in any of these three variants, 100% efficiency was achievedsaid the pharmacist.

SIGHT: Delta variant of COVID-19 is now predominant in Peru: five things you should know

More than 30,000 adults in Brazil, Colombia, the Philippines, South Africa and Belgium participated in the clinical trials and received the vaccine, which is given in two doses to be injected 21 days apart.

The study was funded by the Coalition for the Promotion of Innovations for Epidemic Preparedness (CEPI), an organization that contributed 328 million dollars (280 million euros) to carry it out.

CEPI is a partner of Gavi, the global alliance for public-private vaccines that participates together with the World Health Organization (WHO) in the COVAX project, which pursues an equitable distribution of vaccines worldwide.

CEPI announced last June that it had reached a purchase agreement with Clover whereby the Chinese company will provide COVAX with 414 million doses of vaccines for global use between this year and next, once the Chinese Government and the WHO approve its use.

RELATED VIDEO

IT MAY INTEREST YOU:

  • COVID-19 May Look Like a Cold in the Future, According to AstraZeneca Developer
  • Delta variant of COVID-19 is now predominant in Peru: five things you should know
  • COVID-19 | Europe will decide in October whether to authorize Pfizer’s booster dose
  • Sinopharm will be accepted to travel to the US: reasons to trust the Chinese vaccine
  • COVID-19 | How close are we to the end of the pandemic?
  • Who will the third dose of Pfizer reach in the US?
  • COVID-19 infection may precede Guillain-Barré syndrome in rare cases
  • COVID-19 | “It is a harm to public health for someone to apply more than two doses on their own”
  • COVID-19 | Six billion doses of vaccines have been administered worldwide
  • They find a virus very similar to that of COVID-19 in bats of Laos
  • Brazil and Argentina will produce mRNA vaccines against COVID-19 for the region, PAHO announces
  • Convalescent Plasma: Does This Therapy Work To Treat COVID-19 Patients?
  • COVID-19 killed more in the US than the Spanish flu
  • Johnson & Johnson says a booster of its vaccine increases protection against COVID-19 12 times
  • Long-Term COVID-19: How Much Does It Affect Children?
  • COVID-19 in Peru: More than 47,000 possible cases of reinfection detected
  • Is there evidence that vitamin D protects against severe COVID-19? This says science
  • Coronavirus: Four Factors That Increase Your Risk of Getting COVID-19 After Getting Vaccinated
  • The Booster Dilemma, by Elmer Huerta
  • Pfizer / BioNTech Announces Its Vaccine Is Safe For Children Ages 5 To 11 Years Old
  • FDA Committee Opposes Pfizer Booster Vaccines For Everyone Over 16 Years Old
  • COVID-19 | The coronavirus is evolving to become an airborne virus

Follow us on twitter:


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

Leave a Reply